CardioCell is making significant progress in clinical trials for its indication for chronic heart failure (HF). Chronic HF represents single largest … READ MORE about Chronic Heart Failure
Breakthrough cardiovascular technology derived from allogeneic adult stem cells
Applying stem cell technology for cardiovascular indications is not just an idea anymore.
CardioCell is currently in clinical trials using stem cells to develop “off-the-shelf” products for cardiovascular indication. The company is exploring unmet medical needs in:
Patients with implanted left ventricular assist devices:Innovative stem cell therapeutic strategy that may be transformative for heart failure … READ MORE about Heart Failure in Patients With Left Ventricular Assist Devices
CardioCell’s initial focus is on chronic heart failure indications, but the company is currently exploring the application of our technologies to … READ MORE about Acute Myocardial Infarction
For clinical trials, CardioCell is using cGMP allogeneic stem cells derived from the bone marrow of healthy volunteers.
These cells are manufactured in a licensed cGMP-compliant facility.
CardioCell’s scientific board members and clinical trial principal investigators collaborated on a peer-reviewed paper published in the Journal of Cardiovascular Medicine. For more detail, CLICK HERE.
Clinical Trials Update
Clinical trials to start shortly for innovative stem cell therapeutic strategy that may be transformative for heart failure in patients with left ventricular assist devices. READ MORE HERE
CardioCell retained Objective Capital Partners to help manage current phase of accelerated growth. READ MORE HERE.